GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Capital Expenditure

Alkermes (STU:8AK) Capital Expenditure : €-45.79 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Alkermes's cash flow for capital expenditures for the three months ended in Mar. 2024 was €-8 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was €-45.79 Mil.


Alkermes Capital Expenditure Historical Data

The historical data trend for Alkermes's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Capital Expenditure Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.85 -34.70 -25.68 -36.11 -44.06

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.41 -8.96 -13.54 -15.62 -7.68

Alkermes Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkermes (STU:8AK) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines